Howland Capital Management LLC decreased its position in Idexx Laboratories Inc. (NASDAQ:IDXX) by 12.5% during the third quarter, Holdings Channel reports. The firm owned 258,617 shares of the company’s stock after selling 37,108 shares during the period. Idexx Laboratories comprises approximately 2.7% of Howland Capital Management LLC’s holdings, making the stock its 4th largest position. Howland Capital Management LLC’s holdings in Idexx Laboratories were worth $29,154,000 as of its most recent SEC filing.
Other hedge funds also recently modified their holdings of the company. MSI Financial Services Inc boosted its stake in shares of Idexx Laboratories by 15.2% in the third quarter. MSI Financial Services Inc now owns 964 shares of the company’s stock worth $109,000 after buying an additional 127 shares during the period. Huntington National Bank boosted its stake in Idexx Laboratories by 112.1% in the second quarter. Huntington National Bank now owns 1,190 shares of the company’s stock valued at $111,000 after buying an additional 629 shares during the last quarter. IFP Advisors Inc boosted its stake in Idexx Laboratories by 18.1% in the second quarter. IFP Advisors Inc now owns 1,203 shares of the company’s stock valued at $112,000 after buying an additional 184 shares during the last quarter. Fuller & Thaler Asset Management Inc. acquired a new stake in Idexx Laboratories during the second quarter valued at $121,000. Finally, Tredje AP fonden acquired a new stake in Idexx Laboratories during the second quarter valued at $175,000. 90.84% of the stock is currently owned by institutional investors and hedge funds.
Idexx Laboratories Inc. (NASDAQ:IDXX) traded down 0.5321% during trading on Monday, reaching $119.6301. The company had a trading volume of 218,702 shares. Idexx Laboratories Inc. has a one year low of $63.48 and a one year high of $120.80. The firm’s 50 day moving average is $111.35 and its 200 day moving average is $102.73. The company has a market capitalization of $10.73 billion, a PE ratio of 50.9498 and a beta of 0.48.
Idexx Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Tuesday, November 1st. The company reported $0.62 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.60 by $0.02. Idexx Laboratories had a negative return on equity of 788.91% and a net margin of 12.36%. The business earned $448.30 million during the quarter, compared to analyst estimates of $448.60 million. During the same quarter in the previous year, the company posted $0.48 earnings per share. Idexx Laboratories’s revenue for the quarter was up 10.3% on a year-over-year basis. On average, equities research analysts predict that Idexx Laboratories Inc. will post $2.38 earnings per share for the current year.
IDXX has been the topic of several recent analyst reports. Zacks Investment Research raised Idexx Laboratories from a “hold” rating to a “buy” rating and set a $121.00 price target on the stock in a report on Thursday, August 4th. Bank of America Corp. reaffirmed a “neutral” rating on shares of Idexx Laboratories in a report on Thursday, September 29th. Stifel Nicolaus raised their price target on Idexx Laboratories from $120.00 to $125.00 and gave the company a “buy” rating in a report on Tuesday, August 16th. Canaccord Genuity reaffirmed a “buy” rating on shares of Idexx Laboratories in a report on Tuesday, August 2nd. Finally, Northcoast Research raised Idexx Laboratories from a “sell” rating to a “neutral” rating in a report on Wednesday, August 3rd. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $105.20.
In other Idexx Laboratories news, Director William T. End sold 5,000 shares of the business’s stock in a transaction dated Tuesday, November 8th. The stock was sold at an average price of $109.87, for a total transaction of $549,350.00. Following the completion of the sale, the director now owns 48,654 shares of the company’s stock, valued at $5,345,614.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Jonathan W. Ayers sold 40,000 shares of the business’s stock in a transaction dated Wednesday, November 9th. The shares were sold at an average price of $107.85, for a total value of $4,314,000.00. The disclosure for this sale can be found here. Company insiders own 2.79% of the company’s stock.
About Idexx Laboratories